War in Bosnia. Lessons from Vietnam.

H. Dudley

DOI: https://doi.org/10.1136/BMJ.307.6908.872-C

1993-10-02

British Medical Journal

Abstract:

What problem does this paper attempt to address?

Growth of herpes simplex virus in epidermal keratinocytes determines cutaneous pathogenicity in mice

Y. Yoshida,Zhihong Li,M. Kurokawa,T. Kawana,M. Imakita,K. Shiraki

DOI: https://doi.org/10.1002/jmv.20284

IF: 20.693

2005-03-01

Journal of Medical Virology

Abstract:Herpes simplex viruses (HSV)‐1 and ‐2 isolated from genital lesions were examined for cutaneous pathogenicity and its correlation with cellular tropism. HSV‐1 caused vesiculation, erosion/ulcer, and zosteriform lesions successively, but skin lesions of HSV‐2 developed without vesiculation in some mice, and with statistically significantly less frequent vesiculation than HSV‐1. Thus, the virological type of HSV was correlated with its cutaneous pathogenicity. The growth characteristics of HSV‐1 and ‐2 were compared in cultured human embryonic lung (HEL) fibroblasts, human lung cancer A549 cells, human neonatal epidermal keratinocytes, human neonatal dermal fibroblasts, HeLa cells, and Vero cells. HSV‐2 produced plaques that were 72% times the size of HSV‐1 plaques in epidermal keratinocytes but 230%–500% the size in the other cells. The difference between HSV‐1 and ‐2 in the ratio of plaque size to virus yield in epidermal keratinocytes was much larger (502 times) than the ratio of the other cells (5.57–28.8 times). Keratinocytes are the major constituent of the epidermal layer of the skin and the cells in which vesiculation and erosion/ulceration occur histologically. Therefore, the smaller spread of HSV‐2 in keratinocytes of the epidermal layer and the greater spread in other cells of the dermal layer might reflect its lesser invasiveness in the epidermal layer despite larger invasiveness in the dermal layer, which is reflected in the low incidence of erosion/ulcer of the skin compared to HSV‐1. Thus, the growth of HSV in epidermal keratinocytes appeared to correlate with the cutaneous pathogenicity causing vesiculation in the skin. J. Med. Virol. 75:421–426, 2005. © 2005 Wiley‐Liss, Inc.
Parental reporting of smelly urine and urinary tract infection

S. Struthers,J. Scanlon,K. Parker,J. Goddard,R. Hallett

DOI: https://doi.org/10.1136/adc.88.3.250

2003-03-01

Archives of Disease in Childhood

Abstract:Background: Parents often report that young children have “smelly urine” or a particular urinary odour. There is little evidence that these observations are relevant to the diagnosis of urinary tract infection (UTI). Aims: To determine whether parental reporting of smelly urine is of any relevance to the diagnosis of UTI in children less than 6 years of age. Methods: Parents whose children were having urine collected as part of their admission to a large district hospital were given a simple questionnaire to complete regarding the current smell of their child‘s urine. Parents were asked whether their child‘s urine smelled different from usual or had a particular smell. Microscopy and culture results of the child‘s urine were compared to their parent‘s questionnaire answers to see if there was a association between parental reporting of a different or particular urine smell and a diagnosis of UTI. Results: One hundred and ten questionnaires and urine samples were obtained. Fifty two per cent of parents thought that their child‘s urine smelled different from usual or had a particular smell. Only 6.4% of children were diagnosed as having a UTI. There was no statistically significant association between parental reporting of abnormal urine smell and diagnosis of UTI. Conclusion: In determining whether a young child has a UTI, asking parents about urine smell is unlikely to be of benefit.
[Thulium laser enucleation versus plasma kinetic resection of the prostate in the treatment of benign prostatic hyperplasia]

Wei-Dong Zhang,Wen-Jia Wang,Zhi-Qiang Song,Zhe Ma,Jia-Wei Zhang,Hao-Hao Wang,Jian-Chen Wu

Abstract:Objective: To compare thulium laser enucleation of the prostate (ThuLEP) with plasma kinetic resection of the prostate (PKRP) in the treatment of BPH. Methods: We retrospectively analyzed the medical records of 160 cases of BPH treated by ThuLEP (the observation group, n = 80) or PKRP (the control group, n = 80) in our hospital from January 2021 to December 2023. We recorded the operation time, bladder irrigation time, catheter retention time, hospitalization time, postoperative complications, and pre- and postoperative maximum urinary flow rate (Qmax), residual urine volume (PVR), prostate-specific antigen (PSA) and prostate volume, followed by comparison of the data obtained between the two groups of patients. Results: Compared with the controls, the patients of the observation group showed significantly shorter operation time (［67.25 ± 7.24］ vs ［60.10 ± 5.15］ min, P< 0.05), bladder irrigation time (［46.90 ± 10.77］ vs ［43.24 ± 6.65］ h, P< 0.05), catheterization time (［5.60 ± 1.31］ vs ［5.03 ± 1.24］ d, P< 0.05) and hospitalization time (［7.31 ± 2.00］ vs ［6.55 ± 1.67］ d, P< 0.05), higher Qmax (［18.50 ± 1.24］ vs ［20.68 ± 1.45］ ml/s, P< 0.05), lower PVR (［12.10 ± 3.53］ vs ［10.82 ± 3.10］ ml, P< 0.05), PSA (［4.60 ± 0.78］ vs ［3.38 ± 0.40］ μg/L, P< 0.05) and prostate volume (［25.35 ± 6.46］ vs ［20.12 ± 5.13］ ml, P< 0.05) at 3 months after surgery, but no statistically significant difference in the total incidence of postoperative complications (7.50% ［6/80］ vs 5.00% ［4/80］, P > 0.05). Conclusion: ThuLEP, with its advantages of notable effect, short operation and hospitalization time, significant improvement of urinary flow dynamics and prostate function, deserves clinical promotion for the treatment of BPH.
Efficacy and safety of 120-W thulium:yttrium-aluminum-garnet vapoenucleation of prostates compared with holmium laser enucleation of prostates for benign prostatic hyperplasia.

Kai Hong,Yu-Qing Liu,Jian Lu,Chun-Lei Xiao,Yi Huang,Lu-Lin Ma

DOI: https://doi.org/10.4103/0366-6999.154282

IF: 6.133

2015-01-01

Chinese Medical Journal

Abstract:Background: This study compared the efficacy and safety between 120-W thulium: yttrium-aluminum-garnet (Tm:YAG) vapoenucleation of prostates (ThuVEP) and holmium laser enucleation of prostates (HoLEP) for patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Methods: A retrospective analysis of 88 consecutive patients with symptomatic BPH was carried out, who underwent either 120-W ThuVEP or HoLEP nonrandomly. Patient demographics and peri-operative and 12-month follow-up data were analyzed with the International Prostate Symptom Score (IPSS), quality of life (QoL) score, maximum flow rate (Qmax), postvoid residual urine volume (PVR), and rates of peri-operative and late complications. Results: The patients in each group showed no significant difference in preoperative parameters. Compared with the HoLEP group, patients in the 120-W ThuVEP group required significantly shorter time for laser enucleation (58.3 +/- 12.8 min vs. 70.5 +/- 22.3 min, P = 0.003), and resulted in a significant superiority in laser efficiency (resected prostate weight/laser enucleation time) for 120-W Tm: YAG laser compared to holmium: YAG laser (0.69 +/- 0.18 vs. 0.61 +/- 0.19, P = 0.048). During 1, 6, and 12 months of follow-ups, the procedures did not demonstrate a significant difference in IPSS, QoL score, Qmax, or PVR (P > 0.05). Mean peri-operative decrease of hemoglobin in the HoLEP group was similar to the ThuVEP group (17.1 +/- 12.0 g/L vs. 15.2 +/- 10.1 g/L, P = 0.415). Early and late incidences of complications were low and did not differ significantly between the two groups of 120-W ThuVEP and HoLEP patients (P > 0.05). Conclusions: 120-W ThuVEP and HoLEP are potent, safe and efficient modalities of minimally invasive surgeries for patients with LUTS due to BPH. Compared with HoLEP, 120-W ThuVEP offers advantages of reduction of laser enucleation time and improvement of laser efficiency.
The effect of a monensin controlled-release capsule on the incidence of retained fetal membranes, milk yield and reproductive responses in Holstein cows.

P. Melendez,G. Gonzalez,M. Benzaquen,C. Risco,L. Archbald

DOI: https://doi.org/10.1016/J.THERIOGENOLOGY.2005.11.006

IF: 2.923

2006-07-15

Theriogenology

Abstract:
Impact of Astroglial Connexins on Modafinil Pharmacological Properties.

A. Duchêne,M. Perier,Yan Zhao,Xinhe Liu,J. Thomasson,F. Chauveau,C. Piérard,D. Lagarde,C. Picoli,T. Jeanson,F. Mouthon,Y. Dauvilliers,C. Giaume,Jian-Sheng Lin,M. Charvériat

DOI: https://doi.org/10.5665/sleep.5854

IF: 6.313

2016-06-01

SLEEP

Abstract:STUDY OBJECTIVES Modafinil is a non-amphetaminic wake-promoting compound used as therapy against sleepiness and narcolepsy. Its mode of action is complex, but modafinil has been recently proposed to act as a cellular-coupling enhancer in glial cells, through modulation of gap junctions constituted by connexins. The present study investigated in mice the impact of connexins on the effects of modafinil using connexin inhibitors. METHODS Modafinil was administered alone or combined with inhibitors of astrocyte connexin, meclofenamic acid, or flecainide, respectively, acting on Cx30 and Cx43. Sleep-wake states were monitored in wild-type and narcoleptic orexin knockout mice. A spontaneous alternation task was used to evaluate working memory in wild-type mice. The effects of the compounds on astroglial intercellular coupling were determined using dye transfer in acute cortical slices. RESULTS Meclofenamic acid had little modulation on the effects of modafinil, but flecainide enhanced the wake-promoting and pro-cognitive effects of modafinil. Co-administration of modafinil/flecainide resulted in a marked decrease in the number and duration of direct transitions to rapid eye movement sleep, which are characteristic of narcoleptic episodes in orexin knockout mice. Furthermore, modafinil enhanced the connexin-mediated astroglial cell coupling, whereas flecainide reduced it. Finally, this modafinil-induced effect was reversed by co-administration with flecainide. CONCLUSIONS Our study indicates that flecainide impacts the pharmacological effects of modafinil, likely through the normalization of Cx30-dependent gap junctional coupling in astroglial networks. The enhancement of the wake-promoting, behavioral, and cognitive outcomes of modafinil demonstrated here with flecainide would open new perspectives in the management of sleep disorders such as narcolepsy. COMMENTARY A commentary on this article appears in this issue on page 1175.
A prospective, single-center, randomized clinical trial to evaluate the efficacy of three types of laser vaporization surgeries using a 180-W GreenLight XPS laser, a 300-W diode laser, and a 200-W thulium laser for the treatment of benign prostatic hyperplasia

Tatsunori Okada,Mikifumi Koura,Ryota Sumikawa,Hiroyuki Masaoka,Yoohyun Song,Takashi Dejima,Narihito Seki

DOI: https://doi.org/10.1111/luts.12453

Abstract:Objectives: This study aimed to compare the safety and efficacy of three different laser prostate vaporization surgeries, which were photoselective vaporization of the prostate (PVP), diode laser vaporization (DVP), and thulium laser vaporization (ThuVAP), for the treatment of benign prostatic hyperplasia (BPH) in a randomized clinical trial. Methods: A total of 71 consecutive patients with BPH were included; 23 patients were treated with PVP, 23 with DVP, and 25 with ThuVAP. Patients were evaluated with disease-related symptomatic questionnaires, Quality of Life (QOL) Index, and maximum urinary flow rate (Qmax ) for 12 months. Patients were monitored to record operation/vaporization time, 24-hour hemoglobin/sodium drop, length of catheterization/hospitalization, and perioperative/postoperative complications. Results: In all three groups, patients showed significant and comparable improvements in symptom scores, QOL Index, and Qmax during the 12-month follow-up period. The mean operation/vaporization time was equivalent across all three groups at 69/23 (PVP), 81/34 (DVP), and 76/32 minutes (ThuVAP), while the applied laser energy was lower for PVP at 157 kJ compared to the other two techniques (DVP at 358 kJ, ThuVAP at 240 kJ). The mean vaporization rates per unit energy were significantly different between the three groups (PVP 0.16, DVP 0.09, and ThuVAP 0.09 mL/kJ). There were no significant differences in the main safety profiles between the three groups. Conclusions: Our study demonstrated that these three types of laser surgeries are similar in terms of complications and outcomes, with excellent hemostasis and high patient satisfaction. It was suggested that sufficient tissue vaporization could be achieved using less energy through PVP surgery.
AB060. Long-term Outcome Following Thulium Vaporesection of the Prostate

Haiyi Yu,Zhaocun Zhang,Yaofeng Zhu,Jun Chen,Xuewen Jiang,Hui Meng,Benkang Shi

DOI: https://doi.org/10.21037/tau.2017.s060

2016-01-01

Lasers in Surgery and Medicine

Abstract:Background To analyze the long-term outcomes after thulium vaporesection of the prostate (ThuVaRP). Methods ThuVaRP was performed with the 2-µm, continuous-wave, thulium: yttrium-aluminum-garnet laser, at 70-watt using the vaporesection technique (ThuVaRP). The perioperative and follow-up data were analyzed. Results Median operation time was 44.8±6.5 min, the mean hospital stay was 5.5±1.5 d. 36.24% patients had minor complications, while 0.15% patients got major ones. At discharge, Qmax, PVR volume, IPSS and QoL score were significantly improved and continued to do so at 3, 6, 12, 18, 24, 36, 48, 60 months follow-up. Conclusions Besides efficiency and safety ThuVaRP is also a durable procedure for the treatment of symptomatic benign prostatic obstruction (BPO), with low perioperative and late complications.
1.9Μm-Vela XL Laser Vaporization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study

邱涛,张建军,马合苏提,唐矛,李鸣

DOI: https://doi.org/10.3760/cma.j.issn.1673-4416.2017.01.025

2017-01-01

Abstract:Objectives To compare the effectiveness and complications of 1.9μm-VE1A XL laser vaporization and transurethral resection of the prostate (TURP) in patients with benign prostatic hyperplasia (BPH).Methods In total,72 consecutive patients with BPH entered the study.All patients underwent general and urological evaluations.The primary outcome was improvement in the International Prostate Symptom Score (IPSS),IPSS quality of life (QOL),maximum urinary flow rate (Qmax),re-sidual volume,and complications were compared in the two groups.All patients were divided randomly into the TURP and laser groups.The laser system emitting at a wavelength of 1.9μm,was used for photoselective vaporization of the prostate (VE1A).Results Thirty-six patients in each group underwent VE1A and TURP.The mean age was (63.1 ± 9.1) years and (64.7 ± 10.2)years in the VElA and TURP groups,respectively.There were no statistically significant differences in age,prostate size,prostate-specific antigen concentration,Qmax,preoperative IPSS,or preoperative Qmax between the two groups (P ＞ 0.05).The operation duration was also similar between the groups (P =0.36).The catheterization time was (1.45 ± 0.75) and (2.63 ± 0.49) days in the VE1A and TURP groups,respectively (P ＜ 0.01).The VE1A group had a shorter hospital stay than the TURP group.The 3-month postoperative Qmax increased to (9.90 ± 3.61) and (6.59 ± 6.06)mL/s from baseline in the TURP and VE1A groups,respectively,there was no difference in the increases between the groups (P =0.08).The IPSS and IPSS-QOL were significantly improved with the operation (P ＜ 0.01),and this improvement was similar in both groups P =0.3 and P =0.8,respectively.The complication rate was also similar between the two groups.Conclusions VE1A with a diode laser is as safe and effective as TURP in the treatment of BPH,and the techniques have similar complication rates and functional results.VE1A has the advantage of shorter hospitalization and cath-eter indwelling times and no need for discontinuation of anticoagulant therapy.
Efficacy and Safety of 120-W Thulium

Kai Hong,Yu-Qing Liu,Jian Lu,Chun-Lei Xiao,Yi Huang,Lu-Lin Ma

DOI: https://doi.org/10.4103/0366-6999.154282

IF: 6.133

2015-01-01

Chinese Medical Journal

Abstract:This study compared the efficacy and safety between 120-W thulium:yttrium-aluminum-garnet (Tm:YAG) vapoenucleation of prostates (ThuVEP) and holmium laser enucleation of prostates (HoLEP) for patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).A retrospective analysis of 88 consecutive patients with symptomatic BPH was carried out, who underwent either 120-W ThuVEP or HoLEP nonrandomly. Patient demographics and peri-operative and 12-month follow-up data were analyzed with the International Prostate Symptom Score (IPSS), quality of life (QoL) score, maximum flow rate (Qmax), postvoid residual urine volume (PVR), and rates of peri-operative and late complications.The patients in each group showed no significant difference in preoperative parameters. Compared with the HoLEP group, patients in the 120-W ThuVEP group required significantly shorter time for laser enucleation (58.3 ± 12.8 min vs. 70.5 ± 22.3 min, P = 0.003), and resulted in a significant superiority in laser efficiency (resected prostate weight/laser enucleation time) for 120-W Tm:YAG laser compared to holmium:YAG laser (0.69 ± 0.18 vs. 0.61 ± 0.19, P = 0.048). During 1, 6, and 12 months of follow-ups, the procedures did not demonstrate a significant difference in IPSS, QoL score, Qmax, or PVR (P > 0.05). Mean peri-operative decrease of hemoglobin in the HoLEP group was similar to the ThuVEP group (17.1 ± 12.0 g/L vs. 15.2 ± 10.1 g/L, P = 0.415). Early and late incidences of complications were low and did not differ significantly between the two groups of 120-W ThuVEP and HoLEP patients (P > 0.05).120-W ThuVEP and HoLEP are potent, safe and efficient modalities of minimally invasive surgeries for patients with LUTS due to BPH. Compared with HoLEP, 120-W ThuVEP offers advantages of reduction of laser enucleation time and improvement of laser efficiency.
Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications

Feng Sun,Xincheng Sun,Qinglu Shi,Yuzhang Zhai

DOI: https://doi.org/10.1097/MD.0000000000013360

Abstract:Background: With the progress of surgical techniques and instruments, various minimally invasive surgical therapies were developed to treat benign prostatic hyperplasisa (BPH). However, the efficacy and safety of different transurethral procedures for the treatment of BPH are still undefined. Method: A systematic search was performed for all randomized controlled trials (RCTs), which compared the transurethral procedures for BPH from 1995 to 2016. The clinical baseline characteristics, International Prostate Symptom Score (IPSS), quality of life (QoL), postvoid residual (PVR), maximum flow rate (Qmax), short-term and long-term complications were analyzed using RevMan and ADDIS software. Result: Eighty-eight randomly controlled trials and fifteen procedures were included in the network meta-analysis. HoLEP greatly inproved PVR. TmLRP had the best efficacy in improving QoL score. Diode laser vaporization of prostate was superior in improving IPSS and Qmax. Diode laser through vaporization required the shortest time in catheterization, while Nd:YAG was the longest procedure. For the hospitalization time, TUR was the longest and HoLEP was the shortest. TmLRP was related to the lowest postoperative hemoglobin decrease. TmLEP had the least rates of occurrence of hematuria, reoperation and erectile dysfunction. HoLEP was the best choice to reduce the incidence of recatheterization, urinary retention, urinary tract infection, stress urinary incontinence and retrograde ejaculation. The complications such as blood transfusion, urethral stricture, bladder neck contracture were relatively rare in the patients who underwent diode laser vaporization of prostate. Conclusion: Compared with other transurethral procedures, thulium, holmium and diode lasers were associated with better efficacy and fewer complications.
Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis

Shi-Wei Huang,Chung-You Tsai,Chi-Shin Tseng,Ming-Chieh Shih,Yi-Chun Yeh,Kuo-Liong Chien,Yeong-Shiau Pu,Yu-Kang Tu

DOI: https://doi.org/10.1136/bmj.l5919

2019-11-14

BMJ

Abstract:Abstract Objective To assess the efficacy and safety of different endoscopic surgical treatments for benign prostatic hyperplasia. Design Systematic review and network meta-analysis of randomised controlled trials. Data sources A comprehensive search of PubMed, Embase, and Cochrane databases from inception to 31 March 2019. Study selection Randomised controlled trials comparing vapourisation, resection, and enucleation of the prostate using monopolar, bipolar, or various laser systems (holmium, thulium, potassium titanyl phosphate, or diode) as surgical treatments for benign prostatic hyperplasia. The primary outcomes were the maximal flow rate (Qmax) and international prostate symptoms score (IPSS) at 12 months after surgical treatment. Secondary outcomes were Qmax and IPSS values at 6, 24, and 36 months after surgical treatment; perioperative parameters; and surgical complications. Data extraction and synthesis Two independent reviewers extracted the study data and performed quality assessments using the Cochrane Risk of Bias Tool. The effect sizes were summarised using weighted mean differences for continuous outcomes and odds ratios for binary outcomes. Frequentist approach to the network meta-analysis was used to estimate comparative effects and safety. Ranking probabilities of each treatment were also calculated. Results 109 trials with a total of 13 676 participants were identified. Nine surgical treatments were evaluated. Enucleation achieved better Qmax and IPSS values than resection and vapourisation methods at six and 12 months after surgical treatment, and the difference maintained up to 24 and 36 months after surgical treatment. For Qmax at 12 months after surgical treatment, the best three methods compared with monopolar transurethral resection of the prostate (TURP) were bipolar enucleation (mean difference 2.42 mL/s (95% confidence interval 1.11 to 3.73)), diode laser enucleation (1.86 (−0.17 to 3.88)), and holmium laser enucleation (1.07 (0.07 to 2.08)). The worst performing method was diode laser vapourisation (−1.90 (−5.07 to 1.27)). The results of IPSS at 12 months after treatment were similar to Qmax at 12 months after treatment. The best three methods, versus monopolar TURP, were diode laser enucleation (mean difference −1.00 (−2.41 to 0.40)), bipolar enucleation (0.87 (−1.80 to 0.07)), and holmium laser enucleation (−0.84 (−1.51 to 0.58)). The worst performing method was diode laser vapourisation (1.30 (−1.16 to 3.76)). Eight new methods were better at controlling bleeding than monopolar TURP, resulting in a shorter catheterisation duration, reduced postoperative haemoglobin declination, fewer clot retention events, and lower blood transfusion rate. However, short term transient urinary incontinence might still be a concern for enucleation methods, compared with resection methods (odds ratio 1.92, 1.39 to 2.65). No substantial inconsistency between direct and indirect evidence was detected in primary or secondary outcomes. Conclusion Eight new endoscopic surgical methods for benign prostatic hyperplasia appeared to be superior in safety compared with monopolar TURP. Among these new treatments, enucleation methods showed better Qmax and IPSS values than vapourisation and resection methods. Study registration CRD42018099583.
Effect and Impact of Holmium Laser Versus Thulium Laser Enucleation of the Prostate on Erectile Function

Kai Hong,Yu-qing Liu,Jian Lu,Chun-lei Xiao,Yi Huang,Lu-lin Ma

DOI: https://doi.org/10.13263/j.cnki.nja.2015.03.010

2015-01-01

Abstract:OBJECTIVE:To compare the effect and impact of holmium laser enucleation of the prostate (HoLEP) and 120-W thulium: YAG vapoenucleation of the prostate (ThuVEP) on erectile function in the treatment of benign prostatic hyperplasia (BPH).METHODS:We retrospectively analyzed 93 cases of symptomatic BPH treated by HoLEP or 120 W ThuVEP. We made comparisons between the two groups of patients in the baseline and postoperative clinical and surgical indexes as well as their IPSS, quality of life (QOL), maximum flow rate (Qmax), postvoid residual urine volume (PVR), and IIEF-EF scores before surgery and during the 12-month follow-up.RESULTS:ThuVEP, in comparison with HoLEP, achieved a significantly shorter operation time ([57.6 +/- 12. 8] vs. [70.4 +/- 21.8] min, P = 0.001) and a higher laser efficiency ([0.71 +/- 0.18] vs. [0.62 +/- 0.19] g/min, P = 0. 021). At 1, 6, or 12 months of follow-up, no significant differences were observed in IPSS, OOL, Omax, and PVR between the two groups (P > 0.05). Both the HoLEP and ThuVEP groups showed low incidences of complications and remarkably improved IIEF-EF scores at 12 months postoperatively, but with no significant differences (both P > 0.05). However, in those with relatively normal erectile functions before operation, the mean IIEF-EF score was reduced from 22.8 +/- 2.2 preoperatively to 21.0 +/- 2.7 after HoLEP, (P = 0.036).CONCLUSION:Both HoLEP and 120W ThuVEP are effective and safe in the treatment of BPH. Compared with HoLEP, 120 W ThuVEP has even a higher laser efficiency. However, neither can significantly improve erectile function, and HoLEP may have a short-term negative impact on the relatively normal erectile function of the patient.
Comparison of methods to detect enteroviral genome in frozen and fixed myocardium by polymerase chain reaction.

H. Shimizu,D. Schnurr,J. Burns

1994-10-01

Abstract:BACKGROUND Understanding the pathogenesis of viral myocarditis is linked to the availability of sensitive assays to detect viral genome in clinical material. Recent advances in molecular techniques permit detection of viral-specific RNA in tissue samples. We describe here a comparison of different methods for RNA extraction, reverse transcription, and gene amplification of Coxsackievirus B3 virus in fixed and frozen mouse myocardium. EXPERIMENTAL DESIGN Homogenized Coxsackie B3 virus-infected myocardium was assayed for virus titer and formalin fixed, paraffin-embedded sections from the same heart were subjected to RNA extraction by 3 different methods. Optimal conditions were determined for a one-step assay combining reverse transcription and the polymerase chain reaction to detect enteroviral genome in RNA extracted by these different methods. The presence of amplifiable cDNA was confirmed by amplification of porphobilinogen deaminase mRNA as a positive control. RESULTS Extraction of RNA from paraffin-embedded myocardium after overnight digestion with proteinase K (200 micrograms/ml) and 0.5% sodium dodecyl sulfate was the most efficient of the three methods compared. With our optimized polymerase chain reaction assay, in which the cDNA synthesis and amplification steps are combined, we detected as little as 10 TCID50 of virus from frozen viral stocks and tissue homogenates and 1.0 TCID50 of virus from fixed tissue. CONCLUSIONS This sensitive polymerase chain reaction assay will facilitate examination of archival clinical samples to establish a retrospective diagnosis of enterovirus infection.
Perioperative Outcome of Thulium Laser Enucleation of the Prostate versus Robot-Assisted Simple Prostatectomy: A Propensity Score-Matched Analysis

Friedrich Otto Hartung,Karl-Friedrich Kowalewski,Fehmi Morina,Luisa Egen,Manuel Neuberger,Britta Gruene,Maren Wenk,Maximilian Christian Kriegmair,Philipp Nuhn,Paul Patroi,Niklas Westhoff,Patrick Honeck,Marie-Claire Rassweiler-Seyfried,Maurice Stephan Michel,Jonas Herrmann

DOI: https://doi.org/10.1159/000530627

2023-01-01

Urologia Internationalis

Abstract:Introduction: The aim of this study was to investigate and compare clinical safety and efficiency of Thulium laser enucleation of the prostate (ThuLEP) and robot-assisted simple prostatectomy (RASP) for the treatment of large gland benign prostatic hyperplasia in a tertiary care center. Methods: Perioperative data of 39 patients who underwent RASP in our institution from 2015 to 2021 was collected. Propensity score matching using prostate volume, patient age, and body mass index (BMI) was performed from a database of 1,100 Patients treated by ThuLEP from 2009 to 2021. A total of 76 patients were matched. Preoperative parameters such as BMI, age, and prostate volume, as well as intra- and postoperative parameters such as operation time, resection weight, transfusion rate, postoperative catheterization time, length of hospital stay (LoS), hemoglobin drop, postoperative urinary retention (PUR), Clavien-Dindo Classification (CDC), and the Combined Complication Index (CCI), were evaluated. Results: There was no difference in mean hemoglobin drop (2.2 vs. 1.9 g/dL, p = 0.34), yet endoscopic surgery showed superiority in mean operation time (109 vs. 154 min, p < 0.001), mean postoperative catheterization time (3.3 vs. 7.2 days, p < 0.001), and mean LOS (5.4 vs. 8.4 days, p < 0.001). Complication rates evaluated by CDC ( p = 0.11) and CCI ( p = 0.89) were similar in both groups. Within the documented complications, transfusion rate (0 vs. 3, p = 0.08) and the occurrence of PUR (1 vs. 2, p = 0.5) showed no significant difference. Conclusion: ThuLEP and RASP show similar perioperative efficacy and a low rate of complications. ThuLEP had shorter operation times, shorter catheterization time, and a shorter LoS.

urology & nephrology
Role of Thulium Laser and Holmium Laser in the Surgical Treatment of Benign Prostatic Hyperplasia: A Systemic Review and Meta-Analysis

Jin Wang,Shikui Wu,Mingsheng Wang

DOI: https://doi.org/10.18502/ijph.v53i3.15131

2024-03-13

Iranian Journal of Public Health

Abstract:Background: Patients with benign prostatic hyperplasia are generally treated holmium laser enucleation of the prostate (HoLEP) and thulium laser enucleation of the prostate (ThuLEP). Therefore, it is important to analyze the several surgical procedures used for benign prostatic hyperplasia in terms of their role, effectiveness and safety. Methods: We conducted a meta-analysis by searching databases of PubMed, Google Scholar, and Web of Science. Finally, we selected 10 papers including 2,456 patients treated with of thulium laser and holmium laser in the surgical treatment of benign prostatic hyperplasia. We did the analysis using RevMan 5.0 with the selected studies until 26 October 2023. Results: ThuLEP resulted in a smaller reduction in haemoglobin (MD: -0.22, 95%CI -0.32 to -0.13, P<0.001) and a shorter hospital stay (MD: -0.29, 95%CI -0.38 to -0.20, P <0.001). During the postoperative follow-ups, only the IPSS (MD: -0.03; 95%CI -0.11 to -0.06; P 0.58) at the six-month showed statistically significant differences. Conclusion: ThuLEP has greater security and faster growth than HoLEP.

public, environmental & occupational health
Propensity score-matched analysis comparing perioperative, functional, and safety outcomes between thulium fiber laser and bipolar enucleation of the prostate performed by a single surgeon with two years of follow-up

Armais Albertovich Kamalov,Nikolay Ivanovich Sorokin,Vitaly Kazichanovich Dzitiev,Andrey Alekseevich Strigunov,Olga Yurevna Nesterova,Ilya Vladimirovich Bondar

DOI: https://doi.org/10.4111/icu.20230270

2024-01-01

Investigative and Clinical Urology

Abstract:PURPOSE: To compare perioperative, functional, and safety outcomes between thulium fiber laser enucleation of the prostate (ThuFLEP) and bipolar enucleation of the prostate performed by a single surgeon with use of propensity score (PS)-matched analysis.MATERIALS AND METHODS: Data were from 675 patients, 422 of whom underwent ThuFLEP and bipolar enucleation by a single highly experienced surgeon. ThuFLEP was performed with Fiberlase U1 (IRE Polus Ltd.). Perioperative parameters, safety, and functional outcomes, such as International Prostate Symptom Score (IPSS), quality of life (QoL), postvoid residual volume (PVR), and maximum urinary flow rate (Qmax) were assessed. To control for selection bias, a 1:1 PS-matched analysis was carried out using the following variables as covariates: total prostate volume, preoperative IPSS and early sphincter release.RESULTS: Of 422 patients, 370 (87.7%) underwent ThuFLEP and 52 (12.3%) underwent bipolar enucleation. Operation, enucleation, and morcellation time were comparable between groups before and after PS-matched analysis (p=0.954, p=0.474, p=0.362, respectively). Functional parameters (IPSS, QoL, PVR, Qmax) were also comparable between groups at every time point before and after PS matching. Significant improvements in IPSS, QoL score, Qmax, and PVR were observed during the 24-month follow-up period for both ThuFLEP and bipolar enucleation without any significant differences between groups. Early and late postoperative complications before and after PS-matched analysis were similar.CONCLUSIONS: ThuFLEP was comparable to bipolar enucleation in perioperative characteristics, improvement in voiding parameters, and complication rates. Both procedures were shown to be effective and safe in the management of benign prostatic hyperplasia.

urology & nephrology
Deficiency in Community-Dwelling Elderly Is Not Associated with Age-Related Macular Degeneration 1 – 3

A. Cougnard-Grégoire,B. Merle,J. Korobelnik,M. Rougier,M. Delyfer,C. Féart,M. Goff,J. Dartigues,P. Barberger‐Gateau,C. Delcourt

Abstract:Background: Elderly persons are at elevated risk of vitamin D deficiency, which is involved in various health problems. However, its relation with age-related macular degeneration (AMD) is debated. Objectives: We investigated factors associated with plasma 25-hydroxyvitamin D [25(OH)D] deficiency and the associations between plasma 25(OH)D concentrations and AMD in elderly subjects. Methods: Antioxydants, Lipides Essentiels, Nutrition et maladies OculaiRes (ALIENOR) is a population-based study on eye diseases performed in elderly residents of Bordeaux, France. Plasma 25(OH)D concentrations were assessed from blood samples and categorized as <25 nmol/L (deficiency), 25–49 nmol/L (insufficiency), or $50 nmol/L (sufficiency). AMD was classified as: no AMD, early AMD, and late AMD. Associations between baseline characteristics and plasma 25(OH)D status were examined with multinomial logistic regression analysis. Associations between AMD and plasma 25(OH)D status were estimated using generalized estimating equation logistic regressions. Results: Six hundred ninety-seven subjects with complete data were included. The prevalence of plasma 25(OH)D deficiency and insufficiency were 27.3% and 55.9%, respectively. In multivariate analysis, 25(OH)D deficiency was significantly associated with older age (P 5 0.0007), females (P 5 0.0007), absence of physical activity (P 5 0.01), absence of vitamin D supplementation (P < 0.0001), higher plasma total cholesterol (P 5 0.007), use of fibrates (P < 0.0001), lower alcohol consumption (P5 0.02), and season of blood sampling (P < 0.0001). After adjustment for these covariates and dietary omega-3 polyunsaturated fatty acid intake, smoking, and body mass index, no significant associations were found between early AMD and 25(OH)D insufficiency or deficiency (OR: 0.71, P 5 0.12; OR: 0.73, P 5 0.23, respectively) or with late AMD (OR: 1.04, P 5 0.93; OR: 0.74, P 5 0.59, respectively). Conclusion: These findings underline the very high prevalence of plasma 25(OH)D deficiency in this elderly population but do not support a specific role for vitamin D in AMD. J Nutr 2015;145:1865–72.
Clinical Comparison of Transurethral Enucleation and Resection of Prostate for Treatment of Benign Prostatic Hyperplasia with Monopolar Resectoscope

潘东亮,晋连超,杨冰,张祥华

DOI: https://doi.org/10.3760/cma.j.issn.1673-4416.2013.05.002

2013-01-01

Abstract:Objectives To compare the clinical viability and safety of transurethral enucleation of prostate (M-TUEP) and transurethral resection of prostate(M-TURP) for treatment of benign prostatic hyperplasia(BPH)with monopolar reseetoscope.Methods 60 patients with BPH who had surgical indications and whose volume of prostate was 50ml-75ml were randomized into M-TUEP group and M-TURP group,with 30 patients in each.The preoperative international prostate symptom score(IPSS),the quality of life(QOL),Quantity of maximum flow rate(Qmax),postvoid residual urine volume(PVR),the perioperative operation time,bleeding,weight of resected prostate,mean bladder irrigating time,catheterization time,and hospitalization were recorded.Three months after the operation,the correlative complications,PVR,Qmax and IPSS were observed.All results were statistically analyzed.Results There was no statistically significant difference in preoperative factors between the two groups (P＞ 0.05).The mean operation time,hemorrhage,bladder irrigating time,catheterization time,hospitalization and perioperativelly correlative complications were significantly less in the M-TUEP group than in the M-TURP group (P ＜ 0.05).The mean weight of resected prostate was more heavy in the M-TUEP group than in the M-TURP group(P ＜0.05).There were no significant differences in urinary incontinence,urethral stricture,and retrograde ejaculation between the two groups(P ＞0.05),PVR,IPSS and Qmax were significantly improved(P ＜0.05) at three months postoperatively.Conclusions M-TUEP has the same short-term efficacy as M-TURP for the treatment of symptomatic BPH.The advantages of TUEP is higher safty and efficiency of resection and less complications than M-TURP.And M-TUEP is easy to be mastered for urological surgeons and more fit to be popularized in China than enucleation of prostate with lasers.
Update on the current evidence for Tm:YAG vapoenucleation of the prostate 2014

C Netsch,T Bach,T R W Herrmann,A J Gross

DOI: https://doi.org/10.1007/s00345-014-1417-z

Abstract:Introduction: To evaluate the current role of thulium vapoenucleation of the prostate (ThuVEP) for the treatment of benign prostatic obstruction (BPO). Methods: A Medline search for randomized trials, case series, and comparative studies being published since the initial description of the ThuVEP procedure (2009-2014) was performed to assess the safety, the perioperative morbidity, the efficacy, and the durability of the technique. Results: A total of 14 peer-reviewed original articles, seven case series [level of evidence (LOE) 4] and seven comparative studies (LOE 3b), have been identified. ThuVEP has been shown to be a size-independent, safe, efficacious, and durable procedure for the treatment of BPO in large, prospective, and retrospective series (LOE 4/3b). The feasibility and safety of the ThuVEP procedure has also been confirmed in patients at high cardiopulmonary risk on oral anticoagulants (LOE 4). It has also been demonstrated that the erectile function is not impaired by the ThuVEP procedure (LOE 4). However, published ThuVEP series are from very few centers of excellence not exceeding a LOE of 3b. Randomized controlled trials comparing ThuVEP with standard procedures for the treatment of BPO, namely transurethral resection of the prostate, open prostatectomy, or holmium laser enucleation of the prostate, have not been published so far. Conclusions: ThuVEP appears to be a size-independent, safe, efficacious, and durable procedure for the treatment of BPO (LOE 4/3b). Multicentric PRT are however needed to define the current role of ThuVEP in the armamentarium of minimally invasive transurethral surgery of the prostate.

War in Bosnia. Lessons from Vietnam.

Growth of herpes simplex virus in epidermal keratinocytes determines cutaneous pathogenicity in mice

Parental reporting of smelly urine and urinary tract infection

[Thulium laser enucleation versus plasma kinetic resection of the prostate in the treatment of benign prostatic hyperplasia]

Efficacy and safety of 120-W thulium:yttrium-aluminum-garnet vapoenucleation of prostates compared with holmium laser enucleation of prostates for benign prostatic hyperplasia.

The effect of a monensin controlled-release capsule on the incidence of retained fetal membranes, milk yield and reproductive responses in Holstein cows.

Impact of Astroglial Connexins on Modafinil Pharmacological Properties.

A prospective, single-center, randomized clinical trial to evaluate the efficacy of three types of laser vaporization surgeries using a 180-W GreenLight XPS laser, a 300-W diode laser, and a 200-W thulium laser for the treatment of benign prostatic hyperplasia

AB060. Long-term Outcome Following Thulium Vaporesection of the Prostate

1.9Μm-Vela XL Laser Vaporization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study

Efficacy and Safety of 120-W Thulium

Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications

Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis

Effect and Impact of Holmium Laser Versus Thulium Laser Enucleation of the Prostate on Erectile Function

Comparison of methods to detect enteroviral genome in frozen and fixed myocardium by polymerase chain reaction.

Perioperative Outcome of Thulium Laser Enucleation of the Prostate versus Robot-Assisted Simple Prostatectomy: A Propensity Score-Matched Analysis

Role of Thulium Laser and Holmium Laser in the Surgical Treatment of Benign Prostatic Hyperplasia: A Systemic Review and Meta-Analysis

Propensity score-matched analysis comparing perioperative, functional, and safety outcomes between thulium fiber laser and bipolar enucleation of the prostate performed by a single surgeon with two years of follow-up

Deficiency in Community-Dwelling Elderly Is Not Associated with Age-Related Macular Degeneration 1 – 3

Clinical Comparison of Transurethral Enucleation and Resection of Prostate for Treatment of Benign Prostatic Hyperplasia with Monopolar Resectoscope

Update on the current evidence for Tm:YAG vapoenucleation of the prostate 2014